Search

Your search keyword '"Klopfer, Stephanie O."' showing total 13 results
Start Over Author "Klopfer, Stephanie O." Search Limiters Available in Library Collection
13 results on '"Klopfer, Stephanie O."'

1. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

Author

Molina, Jean-Michel, primary, Yazdanpanah, Yazdan, additional, Afani Saud, Alejandro, additional, Bettacchi, Christopher, additional, Chahin Anania, Carolina, additional, Klopfer, Stephanie O., additional, Grandhi, Anjana, additional, Eves, Karen, additional, Hepler, Deborah, additional, Robertson, Michael N., additional, Hwang, Carey, additional, Hanna, George J., additional, and Correll, Todd, additional

Published
2021
Full Text
View/download PDF

3. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.

Author

Molina, Jean-Michel, Yazdanpanah, Yazdan, Afani Saud, Alejandro, Bettacchi, Christopher, Chahin Anania, Carolina, Klopfer, Stephanie O., Grandhi, Anjana, Eves, Karen, Hepler, Deborah, Robertson, Michael N., Hwang, Carey, Hanna, George J., and Correll, Todd

Published
2022
Full Text
View/download PDF

6. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Author

Reau, Nancy, primary, Robertson, Michael N., additional, Feng, Hwa‐Ping, additional, Caro, Luzelena, additional, Yeh, Wendy W., additional, Nguyen, Bach‐Yen T., additional, Wahl, Janice, additional, Barr, Eliav, additional, Hwang, Peggy, additional, and Klopfer, Stephanie O., additional

Published
2017
Full Text
View/download PDF

13. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide IB clinical probe than rosuvastatin.

Author

Prueksaritanont, Thomayant, Chu, Xiaoyan, Evers, Raymond, Klopfer, Stephanie O., Caro, Luzelena, Kothare, Prajakti A., Dempsey, Cynthia, Rasmussen, Scott, Houle, Robert, Chan, Grace, Cai, Xiaoxin, Valesky, Robert, Fraser, Iain P., and Stoch, S. Aubrey

Subjects
ORGANIC anion transporters, POLYPEPTIDES, ROSUVASTATIN, BREAST cancer treatment, DRUG interactions, THERAPEUTICS
Abstract

AIMS Rosuvastatin and pitavastatin have been proposed as probe substrates for the organic anion-transporting polypeptide (OATP) 1B, but clinical data on their relative sensitivity and selectivity to OATP1B inhibitors are lacking. A clinical study was therefore conducted to determine their relative suitability as OATP1B probes using single oral (PO) and intravenous (IV) doses of the OATP1B inhibitor rifampicin, accompanied by a comprehensive in vitro assessment of rifampicin inhibitory potential on statin transporters. METHODS The clinical study comprised of two separate panels of eight healthy subjects. In each panel, subjects were randomized to receive a single oral dose of rosuvastatin (5 mg) or pitavastatin (1 mg) administered alone, concomitantly with rifampicin (600 mg) PO or IV. The in vitro transporter studies were performed using hepatocytes and recombinant expression systems RESULTS Rifampicin markedly increased exposures of both statins, with greater differential increases after PO vs. IV rifampicin only for rosuvastatin. The magnitudes of the increases in area under the plasma concentration-time curve were 5.7- and 7.6-fold for pitavastatin and 4.4- and 3.3-fold for rosuvastatin, after PO and IV rifampicin, respectively. In vitro studies showed that rifampicin was an inhibitor of OATP1B1 and OATP1B3, breast cancer resistance protein and multidrug resistance protein 2, but not of organic anion transporter 3. CONCLUSIONS The results indicate that pitavastatin is a more sensitive and selective and thus preferred clinical OATP1B probe substrate than rosuvastatin, and that a single IV dose of rifampicin is a more selective OATP1B inhibitor than a PO dose. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results